Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 8/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 8/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.47 |
| ▸ | BCR | P11274 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436175 | 0.90 | BRAF (0.46) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL12397175 | 0.90 | BRAF (0.57) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL15869586 | 0.88 | BRAF (0.45) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL13436291 | 0.86 | DDR1 (0.46) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL13436166 | 0.84 | DDR1 (0.43) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL12465331 | 0.84 | ABL1 (0.55) | BRAFDDR1DDR2ABL1BCR | |
| SCHEMBL13436167 | 0.83 | BRAF (0.55) | BRAFDDR1DDR2ABL1BCR | |
| SCHEMBL12397706 | 0.81 | ABL1 (0.59) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL13436293 | 0.80 | ABL1 (0.64) | BRAFDDR1DDR2KITABL1 | |
| SCHEMBL12397249 | 0.80 | BRAF (0.56) | BRAFABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | claimed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | BRAF 433/4885DDR1 1452/4885DDR2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.